---
title: "VK2735 in Chronic weight management: GLP-1 receptor agonists"
description: "Formulary evidence on VK2735 in Chronic weight management: GLP-1 receptor agonists. Topics: Semaglutide injection and tablets: FDA-approved indications; Semaglutide injection: dosage escalation and maintenance dosages for weight reduction, including 7.2 mg; Semaglutide tablets: administration on an empty stomach and maintenance dosage; Semaglutide injection and tablets: boxed warning for thyroid C-cell tumors; 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/glp-1-receptor-agonists"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: GLP-1 receptor agonists

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.2-1"></a>

### Semaglutide injection and tablets: FDA-approved indications

> “WEGOVY® injection is indicated in combination with a reduced calorie diet and increased physical activity:”
> “To reduce excess body weight and maintain weight reduction long term in:”
> “Adults with overweight in the presence of at least one weight-related comorbid condition.”
> “WEGOVY® tablets are indicated in combination with a reduced calorie diet and increased physical activity:”
> “Concomitant use of WEGOVY® (semaglutide) tablets or WEGOVY® (semaglutide) injection with other semaglutide- containing products or with any other GLP-1 receptor agonist is not recommended.”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### Semaglutide injection: dosage escalation and maintenance dosages for weight reduction, including 7.2 mg

> “The recommended starting dosage of WEGOVY® injection is 0.25 mg administered subcutaneously once weekly.”
> “The maintenance dosage of WEGOVY® for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.”
> “For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Semaglutide tablets: administration on an empty stomach and maintenance dosage

> “Take one WEGOVY® tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces).”
> “After taking a WEGOVY® tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
> “The recommended maintenance dosage of WEGOVY® tablets is 25 mg orally once daily.”
> “If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY® injection 1.7 mg once weekly”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### Semaglutide injection and tablets: boxed warning for thyroid C-cell tumors

> “In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures.”
> “WEGOVY® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Semaglutide tablets: FDA approval for weight management in December 2025

> “PLAINSBORO, N.J., Dec. 22, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy® pill, the first oral GLP-1 medicine for obesity in the US.”
> “1.5 mg starting dose available in early January for $149 per month with savings offers”

Source: [Novo Nordisk Wegovy pill approval announcement (2025)](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html)

<a id="topic-2.2.2.1.2-6"></a>

### Semaglutide 2.4 mg subcutaneous: cardiovascular outcomes in participants without diabetes in SELECT

> “A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.”
> “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).”
> “Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).”

Source: [Lincoff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37952131/)

<a id="topic-2.2.2.1.2-7"></a>

### Semaglutide 2.4 mg subcutaneous: two-year weight change in STEP 5

> “The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001).”
> “Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%).”

Source: [Garvey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9556320/)

<a id="topic-2.2.2.1.2-8"></a>

### American Gastroenterological Association 2022 guideline: recommendations for semaglutide 2.4 mg and liraglutide 3.0 mg

> “The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.”
> “The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.”

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/)

<a id="topic-2.2.2.1.2-9"></a>

### American Diabetes Association 2026 Standards of Care: preferred incretin pharmacotherapy and continuation

> “In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.”
> “Obesity pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight loss goals to maintain the health benefits, as discontinuation often results in recurrence of weight gain and worsening or reemergence of cardiometabolic risk factors.”
> “Clinical trials have shown that sudden discontinuation of semaglutide and tirzepatide results in weight recurrence of one-half to two-thirds of the weight loss within 1 year with reversal of cardiometabolic improvements”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.2-10"></a>

### World Health Organization 2025 guideline: conditional recommendation for long-term GLP-1 therapies

> “WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.”
> “Both recommendations were graded conditional, reflecting that GLP-1 therapies-with or without behavioral therapy-are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.1.2-11"></a>

### Semaglutide injection and tablets: wholesale acquisition cost

| Product and package | Quoted WAC price |
| --- | --- |
| Tablets, 25 mg, 30 tablets per bottle | “$1,349.02” |
| Injection, 2.4 mg dose, 4-pen package | “$1,349.02” |
| Wegovy HD injection, 7.2 mg dose, 4-pen package | “$1,349.02” |

Source: [Novo Nordisk Wegovy pricing information (2026)](https://www.novopricing.com/wegovy.html)

<a id="topic-2.2.2.1.2-12"></a>

### Semaglutide injection and tablets: list price reduction effective January 2027

> “New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses access barriers to our innovative medicines, especially for patients whose out-of-pocket costs are linked to list price”
> “These changes in list price do not have an impact on direct-to-patient, self-pay prices”

Source: [Novo Nordisk list price reduction announcement (2026)](https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html)

<a id="topic-2.2.2.1.2-13"></a>

### Liraglutide and semaglutide: average wholesale price and National Average Drug Acquisition Cost

| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
| --- | --- | --- | --- |
| Liraglutide | “3 mg daily” | “$1,619” | “$1,303” |
| Semaglutide | “2.4 mg once weekly” | “$1,619” | “$1,302” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

Additional sources: [Gilbert et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40539956/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
